Bayesian dose selection design for a binary outcome using restricted response adaptive randomization
Bayesian dose selection design for a binary outcome using restricted response adaptive randomization
In phase II trials, the most efficacious dose is usually not known. Moreover, given limited resources, it is difficult to robustly identify a dose while also testing for a signal of efficacy that would support a phase III trial. Recent designs have sought to be more efficient by exploring multiple …